Compare Danaher Corporation (DHR) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Danaher Corporation trades at $200.48 (market cap $140.88B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.86. The key difference: Danaher Corporation pays a 0.8% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Danaher Corporation is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| DHR | YMAG | |
|---|---|---|
Market Cap | $140.88B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $242.05 | $15.98 |
52-Week Low | $161.91 | $11.00 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
YMAG trades at $11.70, down 0.93% on the day, with technical indicators showing a neutral overall signal. The ETF has demonstrated consistent weekly dividend distributions throughout 2026, with payouts ranging from $0.07 to $0.40 per share. Recent news highlights YMAG's strategy of bundling Magnificent Seven exposure through option income ETFs, though some analysts express concerns about NAV decay and limited upside potential.
The outlook for YMAG hinges on its ability to generate sustainable option income while managing the trade-off between yield and capital appreciation. Key risks include high expense ratios, underperformance during strong bull markets, and dependence on volatility premiums. Institutional interest appears mixed, with the fund's appeal concentrated among income-focused investors seeking Magnificent Seven exposure with enhanced yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
